Garvan Institute of Medical Research

35 items matching your search terms.

Stromal cell diversity associated with immune evasion in human triple-negative breast cancer: Wu, S. Z.; Roden, D. L.; Wang, C.; Holliday, H.; Harvey, K.; Cazet, A. S.; Murphy, K. J.; Pereira, B.; Al-Eryani, G.; Bartonicek, N.; Hou, R.; Torpy, J. R.; Junankar, S.; Chan, C. L.; Lam, C. E.; Hui, M. N.; Gluch, L.; Beith, J.; Parker, A.; Robbins, E.; Segara, D.; Mak, C.; Cooper, C.; Warrier, S.; Forrest, A.; Powell, J.; O'Toole, S.; Cox, T. R.; Timpson, P.; Lim, E.; Liu, X. S.; Swarbrick, A.; EMBO JOURNAL 1 (39) :e104063, 2020 10.15252/embj.2019104063

The Role of the ECM in Lung Cancer Dormancy and Outgrowth: Parker, A. L.; Cox, T. R.; Frontiers in Oncology 10 :1766, 2020 10.3389/fonc.2020.01766

Plasma polymerized nanoparticles effectively deliver dual siRNA and drug therapy in vivo: Michael, P.; Lam, Y. T.; Filipe, E. C.; Tan, R. P.; Chan, A. H. P.; Lee, B. S. L.; Feng, N.; Hung, J.; Cox, T. R.; Santos, M.; Wise, S. G.; Scientific Reports 10 (1) :12836, 2020 10.1038/s41598-020-69591-x

Shedding new light on RhoA signalling as a drug target in vivo using a novel RhoA-FRET biosensor mouse: Nobis, M.; Herrmann, D.; Warren, S. C.; Strathdee, D.; Cox, T. R.; Anderson, K. I.; Timpson, P.; Small GTPases 11 (4) :240-247, 2020 10.1080/21541248.2018.1438024

The Mini-Organo: A rapid high-throughput 3D coculture organotypic assay for oncology screening and drug development: Chitty, J. L.; Skhinas, J. N.; Filipe, E. C.; Wang, S.; Cupello, C. R.; Grant, R. D.; Yam, M.; Papanicolaou, M.; Major, G.; Zaratzian, A.; Da Silva, A. M.; Tayao, M.; Vennin, C.; Timpson, P.; Madsen, C. D.; Cox, T. R.; Cancer Reports 3 (1) :e1209, 2020 10.1002/cnr2.1209

The role of the extracellular matrix and the heparan sulfate proteoglycan Perlecan: Elgundi, Z.; Papanicolaou, M.; Major, G.; Cox, T. R.; Melrose, J.; Whitelock, J. M.; Farrugia, B. L.; Frontiers in Oncology 9 :1482, 2020 10.3389/fonc.2019.01482

CAF subpopulations: A new reservoir of stromal targets in pancreatic cancer: Pereira, B. A.; Vennin, C.; Papanicolaou, M.; Chambers, C. R.; Herrmann, D.; Morton, J. P.; Cox, T. R.; Timpson, P.; Trends in Cancer 5 (11) :724-741, 2019 10.1016/j.trecan.2019.09.010

The importance of developing therapies targeting the biological spectrum of metastatic disease: Zijlstra, A.; Von Lersner, A.; Yu, D.; Borrello, L.; Oudin, M.; Kang, Y.; Sahai, E.; Fingleton, B.; Stein, U.; Cox, T. R.; Price, J. T.; Kato, Y.; Welm, A. L.; Aguirre-Ghiso, J. A.; Board Members of the Metastasis Research, Society; CLINICAL & EXPERIMENTAL METASTASIS 36 (4) :305-309, 2019 10.1007/s10585-019-09972-3

CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan: Vennin, C.; Melenec, P.; Rouet, R.; Nobis, M.; Cazet, A. S.; Murphy, K. J.; Herrmann, D.; Reed, D. A.; Lucas, M. C.; Warren, S. C.; Elgundi, Z.; Pinese, M.; Kalna, G.; Roden, D.; Samuel, M.; Zaratzian, A.; Grey, S. T.; Da Silva, A.; Leung, W.; Mathivanan, S.; Wang, Y.; Braithwaite, A. W.; Christ, D.; Benda, A.; Parkin, A.; Phillips, P. A.; Whitelock, J. M.; Gill, A. J.; Sansom, O. J.; Croucher, D. R.; Parker, B. L.; Pajic, M.; Morton, J. P.; Cox, T. R.; Timpson, P.; Nature Communications 10 (1) :3637, 2019 10.1038/s41467-019-10968-6

Proteomic profiling of human prostate cancer-associated fibroblasts (CAF) reveals LOXL2-dependent regulation of the tumor microenvironment.: Nguyen, E. V.; Pereira, B. A.; Lawrence, M. G.; Ma, X.; Rebello, R. J.; Chan, H.; Niranjan, B.; Wu, Y.; Ellem, S.; Guan, X.; Wu, J.; Skhinas, J. N.; Cox, T. R.; Risbridger, G. P.; Taylor, R. A.; Lister, N. L.; Daly, R. J.; MOLECULAR & CELLULAR PROTEOMICS 18 (7) :1410-1427, 2019 10.1074/mcp.RA119.001496

LOXL1 is regulated by Integrin alpha11 and promotes Non-Small Cell Lung Cancer tumorigenicity: Zeltz, C.; Pasko, E.; Cox, T. R.; Navab, R.; Tsao, M. S.; Cancers 11 (5) :705, 2019 10.3390/cancers11050705

Meeting report: Metastasis Research Society (MRS) 17th Biennial conference and associated Young Investigator Satellite Meeting (YISM) on cancer metastasis: Beadnell, T.; Borriello, L.; Christenson, J.; Fornetti, J.; Guldner, I.; Hanna, A.; Kyjacova, L.; Marinak-Whately, K.; de Melo Martins, P. C.; Rotinen, M.; Te Boekhorst, V.; Cox, T. R.; CLINICAL & EXPERIMENTAL METASTASIS 36 (2) :119-137, 2019 10.1007/s10585-018-09953-y

Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer: Kennedy, S. P.; Han, J. Z. R.; Portman, N.; Nobis, M.; Hastings, J. F.; Murphy, K. J.; Latham, S. L.; Cadell, A. L.; Miladinovic, D.; Marriott, G. R.; O'Donnell, Y. E. I.; Shearer, R. F.; Williams, J. T.; Munoz, A. G.; Cox, T. R.; Watkins, D. N.; Saunders, D. N.; Timpson, P.; Lim, E.; Kolch, W.; Croucher, D. R.; BREAST CANCER RESEARCH 21 (1) :43, 2019 10.1186/s13058-019-1127-y

The extracellular matrix as a key regulator of intracellular signalling networks: Hastings, J. F.; Skhinas, J. N.; Fey, D.; Croucher, D. R.; Cox, T. R.; BRITISH JOURNAL OF PHARMACOLOGY 176 (1) :82-92, 2019 10.1111/bph.14195

Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer: Chou, A.; Froio, D.; Nagrial, A. M.; Parkin, A.; Murphy, K. J.; Chin, V. T.; Wohl, D.; Steinmann, A.; Stark, R.; Drury, A.; Walters, S. N.; Vennin, C.; Burgess, A.; Pinese, M.; Chantrill, L. A.; Cowley, M. J.; Molloy, T. J.; Waddell, N.; Johns, A.; Grimmond, S. M.; Chang, D. K.; Biankin, A. V.; Sansom, O. J.; Morton, J. P.; Grey, S. T.; Cox, T. R.; Turchini, J.; Samra, J.; Clarke, S. J.; Timpson, P.; Gill, A. J.; Pajic, M.; GUT 67 (12) :2142-2155, 2018 10.1136/gutjnl-2017-315144